ABIVAX SA (2X1.DE) Fundamental Analysis & Valuation

FRA:2X1 • FR0012333284

Current stock price

95 EUR
-1 (-1.04%)
Last:

This 2X1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. 2X1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 2X1 has reported negative net income.
  • In the past year 2X1 has reported a negative cash flow from operations.
  • 2X1 had negative earnings in each of the past 5 years.
  • In the past 5 years 2X1 always reported negative operating cash flow.
2X1.DE Yearly Net Income VS EBIT VS OCF VS FCF2X1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of 2X1 (-146.87%) is worse than 82.28% of its industry peers.
Industry RankSector Rank
ROA -146.87%
ROE N/A
ROIC N/A
ROA(3y)-70.48%
ROA(5y)-60.32%
ROE(3y)-451.51%
ROE(5y)-460.64%
ROIC(3y)N/A
ROIC(5y)N/A
2X1.DE Yearly ROA, ROE, ROIC2X1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for 2X1 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2X1.DE Yearly Profit, Operating, Gross Margins2X1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. 2X1.DE Health Analysis

2.1 Basic Checks

  • 2X1 has more shares outstanding than it did 1 year ago.
  • 2X1 has more shares outstanding than it did 5 years ago.
  • 2X1 has a worse debt/assets ratio than last year.
2X1.DE Yearly Shares Outstanding2X1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
2X1.DE Yearly Total Debt VS Total Assets2X1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 15.92 indicates that 2X1 is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 15.92, 2X1 belongs to the best of the industry, outperforming 96.20% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 15.92
ROIC/WACCN/A
WACCN/A
2X1.DE Yearly LT Debt VS Equity VS FCF2X1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • 2X1 has a Current Ratio of 0.77. This is a bad value and indicates that 2X1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 2X1 has a worse Current ratio (0.77) than 74.68% of its industry peers.
  • 2X1 has a Quick Ratio of 0.77. This is a bad value and indicates that 2X1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.77, 2X1 is not doing good in the industry: 73.42% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
2X1.DE Yearly Current Assets VS Current Liabilites2X1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. 2X1.DE Growth Analysis

3.1 Past

  • 2X1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.52%, which is quite good.
EPS 1Y (TTM)18.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, 2X1 will show a decrease in Earnings Per Share. The EPS will decrease by -8.10% on average per year.
  • Based on estimates for the next years, 2X1 will show a very strong growth in Revenue. The Revenue will grow by 171.60% on average per year.
EPS Next Y-20.7%
EPS Next 2Y33.3%
EPS Next 3Y-1.13%
EPS Next 5Y-8.1%
Revenue Next Year29.38%
Revenue Next 2Y13.87%
Revenue Next 3Y266.42%
Revenue Next 5Y171.6%

3.3 Evolution

2X1.DE Yearly Revenue VS Estimates2X1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
2X1.DE Yearly EPS VS Estimates2X1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. 2X1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 2X1. In the last year negative earnings were reported.
  • Also next year 2X1 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
2X1.DE Price Earnings VS Forward Price Earnings2X1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
2X1.DE Per share data2X1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.3%
EPS Next 3Y-1.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 2X1.DE Dividend Analysis

5.1 Amount

  • No dividends for 2X1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

2X1.DE Fundamentals: All Metrics, Ratios and Statistics

ABIVAX SA

FRA:2X1 (3/26/2026, 7:00:00 PM)

95

-1 (-1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-15
Earnings (Next)03-23
Inst Owners39.91%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.51B
Revenue(TTM)N/A
Net Income(TTM)-176.24M
Analysts85.71
Price Target128.03 (34.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.03%
PT rev (3m)12.19%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-16.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-32.45%
Revenue NY rev (3m)-32.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.8
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.71
OCFYN/A
SpS0
BVpS-0.61
TBVpS-0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.48%
ROA(5y)-60.32%
ROE(3y)-451.51%
ROE(5y)-460.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z 15.92
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.18%
Cap/Depr(5y)310.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.26%
EPS Next Y-20.7%
EPS Next 2Y33.3%
EPS Next 3Y-1.13%
EPS Next 5Y-8.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year29.38%
Revenue Next 2Y13.87%
Revenue Next 3Y266.42%
Revenue Next 5Y171.6%
EBIT growth 1Y-35.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.04%
EBIT Next 3Y16%
EBIT Next 5YN/A
FCF growth 1Y-141.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.43%
OCF growth 3YN/A
OCF growth 5YN/A

ABIVAX SA / 2X1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ABIVAX SA (2X1.DE) stock?

ChartMill assigns a fundamental rating of 1 / 10 to 2X1.DE.


What is the valuation status of ABIVAX SA (2X1.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ABIVAX SA (2X1.DE). This can be considered as Overvalued.


What is the profitability of 2X1 stock?

ABIVAX SA (2X1.DE) has a profitability rating of 0 / 10.